These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 33879556

  • 1. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
    Ishibashi M, Yamamoto J, Ito T, Handa H, Sunakawa-Kii M, Inokuchi K, Morita R, Tamura H.
    Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
    [Abstract] [Full Text] [Related]

  • 2. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
    Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, Moriya K, Choi I, Tamada K, Inokuchi K.
    Cancer Immunol Res; 2016 Sep 02; 4(9):779-88. PubMed ID: 27440711
    [Abstract] [Full Text] [Related]

  • 3. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
    Davis LN, Walker ZJ, Reiman LT, Parzych SE, Stevens BM, Jordan CT, Forsberg PA, Sherbenou DW.
    Clin Cancer Res; 2024 Jul 15; 30(14):3023-3035. PubMed ID: 38723281
    [Abstract] [Full Text] [Related]

  • 4. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
    Kearl TJ, Jing W, Gershan JA, Johnson BD.
    J Immunol; 2013 Jun 01; 190(11):5620-8. PubMed ID: 23616570
    [Abstract] [Full Text] [Related]

  • 5. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
    Mougiakakos D, Bach C, Böttcher M, Beier F, Röhner L, Stoll A, Rehli M, Gebhard C, Lischer C, Eberhardt M, Vera J, Büttner-Herold M, Bitterer K, Balzer H, Leffler M, Jitschin S, Hundemer M, Awwad MHS, Busch M, Stenger S, Völkl S, Schütz C, Krönke J, Mackensen A, Bruns H.
    Cancer Immunol Res; 2021 Mar 01; 9(3):265-278. PubMed ID: 33563611
    [Abstract] [Full Text] [Related]

  • 6. Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
    Costa F, Das R, Kini Bailur J, Dhodapkar K, Dhodapkar MV.
    Front Immunol; 2018 Mar 01; 9():2204. PubMed ID: 30319648
    [Abstract] [Full Text] [Related]

  • 7. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J, Yenchitsomanus PT.
    Biomed Pharmacother; 2023 Dec 01; 168():115691. PubMed ID: 37844355
    [Abstract] [Full Text] [Related]

  • 8. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.
    Fedele PL, Willis SN, Liao Y, Low MS, Rautela J, Segal DH, Gong JN, Huntington ND, Shi W, Huang DCS, Grigoriadis G, Tellier J, Nutt SL.
    Blood; 2018 Nov 15; 132(20):2166-2178. PubMed ID: 30228232
    [Abstract] [Full Text] [Related]

  • 9. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway.
    Chen D, Tang P, Liu L, Wang F, Xing H, Sun L, Jiang Z.
    Cell Cycle; 2018 Nov 15; 17(7):858-867. PubMed ID: 29493401
    [Abstract] [Full Text] [Related]

  • 10. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z, Sun R, Zhao HJ, Fu D, Zhong HJ, Weng XQ, Qu B, Zhao Y, Wang L, Zhao WL.
    Mol Cancer; 2019 Mar 30; 18(1):54. PubMed ID: 30925928
    [Abstract] [Full Text] [Related]

  • 11. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
    Wu Y, Chen W, Xu ZP, Gu W.
    Front Immunol; 2019 Mar 30; 10():2022. PubMed ID: 31507611
    [Abstract] [Full Text] [Related]

  • 12. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC.
    Clin Cancer Res; 2015 Oct 15; 21(20):4607-18. PubMed ID: 25979485
    [Abstract] [Full Text] [Related]

  • 13. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A, Peng D, Guo H, Ben Y, Zuo X, Wu F, Yang X, Teng F, Li Z, Qian X, Qin FX.
    Sci Rep; 2017 Feb 16; 7():42687. PubMed ID: 28202921
    [Abstract] [Full Text] [Related]

  • 14. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
    Walker ZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW.
    Clin Cancer Res; 2021 Feb 01; 27(3):819-830. PubMed ID: 33109736
    [Abstract] [Full Text] [Related]

  • 15. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
    Liu J, Song T, Zhou W, Xing L, Wang S, Ho M, Peng Z, Tai YT, Hideshima T, Anderson KC, Cang Y.
    Leukemia; 2019 Jan 01; 33(1):171-180. PubMed ID: 30026574
    [Abstract] [Full Text] [Related]

  • 16. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
    Kraman M, Faroudi M, Allen NL, Kmiecik K, Gliddon D, Seal C, Koers A, Wydro MM, Batey S, Winnewisser J, Young L, Tuna M, Doody J, Morrow M, Brewis N.
    Clin Cancer Res; 2020 Jul 01; 26(13):3333-3344. PubMed ID: 32299814
    [Abstract] [Full Text] [Related]

  • 17. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
    Qin G, Wang X, Ye S, Li Y, Chen M, Wang S, Qin T, Zhang C, Li Y, Long Q, Hu H, Shi D, Li J, Zhang K, Zhai Q, Tang Y, Kang T, Lan P, Xie F, Lu J, Deng W.
    Nat Commun; 2020 Apr 03; 11(1):1669. PubMed ID: 32245950
    [Abstract] [Full Text] [Related]

  • 18. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.
    Jelinek T, Paiva B, Hajek R.
    Front Immunol; 2018 Apr 03; 9():2431. PubMed ID: 30505301
    [Abstract] [Full Text] [Related]

  • 19. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
    Ocio EM, Fernández-Lázaro D, San-Segundo L, López-Corral L, Corchete LA, Gutiérrez NC, Garayoa M, Paíno T, García-Gómez A, Delgado M, Montero JC, Díaz-Rodríguez E, Mateos MV, Pandiella A, Couto S, Wang M, Bjorklund CC, San-Miguel JF.
    Leukemia; 2015 Mar 03; 29(3):705-14. PubMed ID: 25102946
    [Abstract] [Full Text] [Related]

  • 20. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
    Xu Q, Hou YX, Langlais P, Erickson P, Zhu J, Shi CX, Luo M, Zhu Y, Xu Y, Mandarino LJ, Stewart K, Chang XB.
    BMC Cancer; 2016 May 03; 16():297. PubMed ID: 27142104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.